{"url_path":"/sec/phat/8-k/2026-05-21/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1783183/0001193125-26-234379-index.html","accession_number":"0001193125-26-234379","cik":"0001783183","ticker":"PHAT","issuer_name":"Phathom Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1783183/0001193125-26-234379-index.html","primary_entity_key":"0001783183","primary_entity_name":"Phathom Pharmaceuticals, Inc."},"word_count":296,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn May 19, 2026, Phathom Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders voted on the matters disclosed in the Company’s definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 7, 2026 (the “Proxy Statement”). The final voting results for the matters submitted to a vote of stockholders were as follows:\n\nProposal No. 1 - Election of Class I Directors\n\nAt the Annual Meeting, the Company’s stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:\n\n \n\nDirectors\n\n  \nVotes For\n \n  \nWithheld\n \n  \nBroker Non-Votes\n \n\nSteven Basta\n\n  \n \n42,656,800\n \n  \n \n4,490,781\n \n  \n \n17,487,652\n \n\nTheodore R. Schroeder\n\n  \n \n42,578,532\n \n  \n \n4,569,049\n \n  \n \n17,487,652\n \n\nMark Stenhouse\n\n  \n \n41,249,990\n \n  \n \n5,897,591\n \n  \n \n17,487,652\n \n\nProposal No. 2 - Ratification of Independent Registered Public Accounting Firm\n\nThe Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026:\n\n \n\nVotes For\n\n  \nVotes Against\n  \nAbstentions\n\n64,482,757\n\n  \n49,661\n  \n102,815\n\nProposal No. 3 – Approval of the Compensation of the Named Executive Officers (“say-on-pay”)\n\nThe Company’s stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers:\n\n \n\nVotes For\n\n  \n\nVotes Against\n\n  \n\nAbstentions\n\n  \n\nBroker Non-Votes\n\n44,449,761\n\n  \n2,532,145\n  \n165,675\n  \n17,487,652\n\nNo other matters were considered or voted upon at the Annual Meeting.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nPHATHOM PHARMACEUTICALS, INC.\n\nDate: May 21, 2026\n \n\n \nBy:\n \n/s/ Anne Marie Cook\n\n \n\n \n\n \nAnne Marie Cook\n\n \n\n \n\n \nChief Legal Officer and Secretary"}